ArticleJournal of translational medicine2026
B7-H3 interaction with cMet enhances lipolysis to drive malignant progression of glioma via pSTAT3-ATGL axis.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundAlthough metabolic dysregulation serves as a pivotal hallmark in glioma, the detailed information about the lipid metabolism regulation is largely unknown. In the context of this investigation, we have identified B7-H3 - an immune checkpoint molecule of the B7 family - as a regulator of lipid metabolism in glioma.
methodsA series of enrichment analyses were applied to explore the interaction between metabolic reprogramming and prognosis in glioma. The expression and prognostic value of B7-H3 were detected in both public databases and clinical samples. Furthermore, the effect of B7-H3 on Glioma cells malignance and lipid metabolism was evaluated through in vivo and in vitro functional experiments. Finally, the molecular mechanism of B7-H3 was investigated by the study of transcriptome sequencing and key interacting proteins.
resultsThe metabolism associated genes (MAG) were firstly screened from the prognosis related differentially expressed genes (DEG) using the TCGA and verified CGGA derived primary and recurrent cohorts of glioma patients, and the immune checkpoint molecule CD276 (B7-H3) was selected due its significant poor prognosis correlation in both primary and recurrent glioma. Furthermore, both RNA sequencing and untargeted metabolomics profiling confirmed a strong correlation between B7-H3 and lipid metabolism in glioma. Notably, B7-H3 showed a significant positive correlation with lipolytic enzyme ATGL (PNPLA2) according to the above transcriptomic data and CGGA database of glioma. However, the receptors of B7-H3 on cancer cells remained poorly understood. Here, we reported that B7-H3 modulated abnormal lipolysis during glioma progression by forming a complex with cMet, and subsequent simultaneous promoting the phosphorylation of STAT3 and expression of ATGL. More importantly, B7-H3 protein level was associated with poor prognosis and correlated with ATGL status in glioma.
conclusionsOur results define B7-H3 as a lipolysis related factor that acts by driving glioma malignancy via the cMet-pSTAT3-ATGL pathway, thereby nominating both B7-H3 and ATGL as potential therapeutic targets for glioma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.